About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? [email protected]

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

A Study of DLX105-DMP in Subjects With Plaque Psoriasis

NCT04203433·4 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

DelArrivo, Inc.

Age

18–75

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Signed and dated informed consent.
Subjects aged 18-75 years.
Male subject, or if female, must be surgically sterile, post-menopausal, or using acceptable birth control.
Stable chronic mild-to-moderate plaque psoriasis.

You may not be if

Non-plaque-type psoriasis only (e.g., pustular, erythrodermic and guttate psoriasis, palmar, or plantar) at Screening.
Drug-induced psoriasis (i.e., new onset or exacerbation from beta-blockers, calcium channel inhibitors or lithium) within 3 months prior to Day 1.
Ongoing use of psoriasis treatments or inadequate duration of washout prior to Day 1

The record

StatusCompleted

PhasePhase 1

Taking part10

StartedMar 2022

UpdatedMay 3, 2023

Conditions

Plaque Psoriasis

Where4

DelArrivo Investigational Site
Alpharetta, Georgia, United States
DelArrivo Investigational Site
Philadelphia, Pennsylvania, United States
DelArrivo Investigational Site
San Antonio, Texas, United States

Clareo Health | A Study of DLX105-DMP in Subjects With Plaque Psoriasis